Department of Physiology and Biophysics, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A.
Department of Surgery, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A.
Clin Sci (Lond). 2022 Sep 30;136(18):1347-1366. doi: 10.1042/CS20220572.
The metabolic-associated fatty liver disease (MAFLD) is a condition of fat accumulation in the liver in combination with metabolic dysfunction in the form of overweight or obesity and insulin resistance. It is also associated with an increased cardiovascular disease risk, including hypertension and atherosclerosis. Hepatic lipid metabolism is regulated by a combination of the uptake and export of fatty acids, de novo lipogenesis, and fat utilization by β-oxidation. When the balance between these pathways is altered, hepatic lipid accumulation commences, and long-term activation of inflammatory and fibrotic pathways can progress to worsen the liver disease. This review discusses the details of the molecular mechanisms regulating hepatic lipids and the emerging therapies targeting these pathways as potential future treatments for MAFLD.
代谢相关脂肪性肝病(MAFLD)是一种肝脏脂肪堆积的病症,伴有超重或肥胖和胰岛素抵抗等代谢功能障碍。它还与心血管疾病风险增加相关,包括高血压和动脉粥样硬化。肝内脂质代谢受脂肪酸摄取和输出、从头合成和β氧化利用的综合调控。当这些途径之间的平衡被改变时,肝内脂质开始堆积,长期激活炎症和纤维化途径会导致肝病恶化。本综述讨论了调节肝内脂质的分子机制的详细信息,以及针对这些途径的新兴治疗方法作为 MAFLD 的潜在未来治疗方法。